HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Esperion Therapeutics (NASDAQ:ESPR) and maintained a $16 price target, as stated by analyst Joseph Pantginis.
August 12, 2024 | 5:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Esperion Therapeutics and maintained a $16 price target, indicating continued confidence in the company's prospects.
The reiteration of a Buy rating and maintenance of a $16 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100